Skip to main content
. 2021 Aug 27;11:103–111. doi: 10.1016/j.ibneur.2021.08.003

Fig. 3.

Fig. 3

Forest plots of the network meta-analysis of the efficacy and safety of anti-CD20 mAbs, including the risk of developing annualized relapse rate (A), serious adverse events (B), any adverse event (C), and discontinuation of treatments due to adverse events (D), as well as the odds of relapse-free events (E).